Abstract

Aim: Breast cancer is the most common type of cancer in women and it is the second most common cause of mortality in women. In the last 20 years, there has been an increase in the incidence of breast cancer, while mortality has decreased. The androgen receptor (AR) belongs to the same family as other steroid hormone receptor. The androgen receptor (AR) belongs to the same family as other steroid hormone receptors. Therefore, it shows high structural, functional, and topographic similarity to estrogen and progesterone receptors. In this study, we aimed to investigate the relationship between androgen receptor expression and breast cancer prognostic factors. Material and Methods: Mastectomy materials belonging to 26 cases examined between 2016-2019 in the Department of Surgical Oncology, Faculty of Medicine, Sivas Cumhuriyet University. Clinical and pathological features such as retrospectively patient age, tumor type, tumor size, lymph node involvement, lymphovascular invasion, pathological stage, tumor grade, Ki-67 index, HER-2 / neu, androgen receptor, estrogen receptor, progesterone receptor were obtained from patient files. Results As a result of statistical analysis, a statistically significant relationship was found between AR expression and lymphovascular invasion of tumors, lymph node involvements, estrogen receptor, progesterone receptor, HER-2 / neu expression, and Ki-67 index. There was no significant difference between AR expression and menopausal status, tumor grade, tumor diameter. A negative correlation was observed between AR expression and pathological stage. Conclusions: As a result, androgen receptor positivity is associated with better clinical outcomes. Its correlation with both estrogen receptor and progesterone receptor positivity suggests that the predictive and prognostic value of this receptor can be increased by assessing the condition of the patient's estrogen receptor and progesterone receptors. Key words: Androgen receptor, Breast cancer, prognosis Special Issue of Health Sciences DOI: 10.7176/JSTR/6-03-34

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.